JPH0729932B2 - Animal malignant tumor cell growth inhibitor - Google Patents
Animal malignant tumor cell growth inhibitorInfo
- Publication number
- JPH0729932B2 JPH0729932B2 JP61148129A JP14812986A JPH0729932B2 JP H0729932 B2 JPH0729932 B2 JP H0729932B2 JP 61148129 A JP61148129 A JP 61148129A JP 14812986 A JP14812986 A JP 14812986A JP H0729932 B2 JPH0729932 B2 JP H0729932B2
- Authority
- JP
- Japan
- Prior art keywords
- malignant tumor
- tumor cell
- cell growth
- growth inhibitor
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、人を含む動物の悪性腫瘍細胞抑制剤に関する
ものである。TECHNICAL FIELD The present invention relates to an agent for suppressing malignant tumor cells in animals including humans.
従来の技術 動物の悪性腫瘍細胞の培養後培地より前記悪性腫瘍細胞
を除いて抽出したものからなる動物の悪性腫瘍細胞増殖
抑制剤は特開昭59−33223号として提案されている。2. Description of the Related Art An animal malignant tumor cell growth inhibitor comprising an animal malignant tumor cell after culturing and excluding the above malignant tumor cells and extracted has been proposed in JP-A-59-33223.
発明が解決すべき問題点 本発明は前記従来の技術によって得られた悪性腫瘍細胞
増殖抑制剤よりも純粋で抑制効果の高い動物の悪性腫瘍
細胞増殖抑制剤を提供することを目的とするものであ
る。Problems to be Solved by the Invention It is an object of the present invention to provide a malignant tumor cell growth inhibitor for animals that is purer and has a higher inhibitory effect than the malignant tumor cell growth inhibitor obtained by the above-mentioned conventional technique. is there.
問題点を解決するための手段 本発明の人を含む動物の悪性腫瘍細胞増殖抑制剤は、ヒ
ト腎細胞癌由来樹立株細胞Ｈ・Ｒ・Ｃ、マウス由来の株
化細胞LLC等の動物の悪性腫瘍細胞を10％牛胎児血清添
加のＥ−MEM（イーグルスミニエッセンシャルメディア
ム）等の培地で培養し、その後無血清培地等の抽出用培
地に移して35〜37℃で４〜７日培養し、それから前記悪
性腫瘍細胞を除くことにより、抽出培養液を得、この粗
製品に原液の1/25量のメタノールを加えて溶解し、その
上澄みをメタノールで膨潤したビーズ状のハイドロキシ
プロピル化デキストランゲル（米国ファルマシアファイ
ンケミカル社製LH−20）を直径10cm,長さ120cm充填した
カラムで１時間800ミリリットルの流量を通しメタノー
ルで溶出し、7.25〜9.0時間の間に流出する区分を分画
したものよりなることを特徴とする。Means for Solving Problems The malignant tumor cell growth inhibitor for animals including humans of the present invention is a malignant animal such as human renal cell carcinoma-derived established cell line HR / C and mouse-derived cell line LLC. Tumor cells were cultured in a medium such as E-MEM (Eagles Mini Essential Mediam) supplemented with 10% fetal bovine serum, and then transferred to an extraction medium such as a serum-free medium and cultured at 35 to 37 ° C for 4 to 7 days. , And then the above-mentioned malignant tumor cells were removed to obtain an extracted culture solution, and this crude product was dissolved by adding 1/25 amount of methanol of the stock solution, and the supernatant was swollen with methanol to form bead-shaped hydroxypropylated dextran gel. (LH-20 manufactured by Pharmacia Fine Chemicals, USA) was packed in a column packed with a diameter of 10 cm and a length of 120 cm at a flow rate of 800 ml for 1 hour to elute with methanol, and fractions flowing out during 7.25 to 9.0 hours were fractionated. Characterized in that it comprises more.
前記分取に際しての検出器としては254nmの波長に対す
る吸光度を計測する紫外線検出器を用いる。この分画
は、数種のアミノ酸を主成分とし、糖質を含まず、NMR
（該磁気共鳴吸収），ガスクロマトグラフィーで乳酸様
シグナルを示す物質の含量は微小である。An ultraviolet detector that measures absorbance at a wavelength of 254 nm is used as a detector for the fractionation. This fraction is mainly composed of several amino acids, contains no sugar, and
(The magnetic resonance absorption), the content of the substance showing a lactic acid-like signal by gas chromatography is minute.
そして、分子量は1000以下であり、水との親和性が極め
て高く、無機塩と結合し易く、水，メタノールに可溶で
あって、一般に有機溶剤に溶けにくい性状を有してい
る。It has a molecular weight of 1,000 or less, has a very high affinity with water, easily binds to an inorganic salt, is soluble in water and methanol, and generally has a property of being hardly soluble in an organic solvent.
また、沸騰水浴中に１時間置いた場合、PH2〜10の範囲
で常温中に一昼夜放置した場合およびプロナーゼ処理及
びグリコシターゼ処理等に対してその活性は失われない
ものである。In addition, the activity is not lost when it is placed in a boiling water bath for 1 hour, when it is left at room temperature in the range of PH 2 to 10 for a whole day and night, and when it is treated with pronase and glycosidase.
実施例 １）使用細胞 動物の悪性腫瘍細胞としてヒト腎細胞癌由来樹立株細胞
HRCを使用した。Example 1) Cells used Human renal cell carcinoma-derived established cell line as malignant tumor cell of animal
HRC was used.
２）培養 成長用培地には10％牛胎児血清を添加したＥ−MEMに4g/
のグルコースを添加したものを用い、抽出用培地とし
ては、血清無添加のＥ−MEMにグルコースを２〜5g/添
加したものを使用した。2) Culture 4g / E-MEM supplemented with 10% fetal bovine serum was used as the growth medium.
Was used, and the medium for extraction used was E-MEM containing no serum and 2 to 5 g of glucose added.
まず成長用培地を用い、培養器に飽和状態になるまで悪
性腫瘍細胞を増殖し、その後無血清のＥ−MEM培地で洗
って血清を除く。次に、これを抽出用培地に移して35〜
37℃で培養し、抽出培養液を得る。First, a growth medium is used to grow malignant tumor cells in a culture vessel until the cells are saturated, and then washed with a serum-free E-MEM medium to remove serum. Next, transfer this to the extraction medium and
Incubate at 37 ℃ to obtain the extraction medium.
３）精製法 まず、悪性腫瘍細胞を除去して採取された抽出培養液を
直径60mm、内容積250ml、ポリカーボネート製の蓋付分
離容器に入れ遠心分離機にセットし毎分１万回転で10分
間遠心分離し、その上澄みを採取し、さらにこれを減圧
蒸発乾固して粗製品を得る。3) Purification method First, the extracted culture solution obtained by removing malignant tumor cells is placed in a separation container with a diameter of 60 mm, an internal volume of 250 ml, a polycarbonate lid, and set in a centrifuge for 10 minutes at 10,000 rpm. Centrifuge, collect the supernatant, and evaporate to dryness under reduced pressure to obtain a crude product.
その後、これに抽出培養液の1/25量のメタノールを加
え、溶解して直径60mm、100mm、内容積250mlでポリカー
ボネート製の蓋付分離器に入れ遠心分離機にセットし遠
心分離（１万回転,10分間）し、その上澄み液３分を
メタノールで膨潤した米国ファルマシアファインケミカ
ル社製LH−20よりなる固定相充填のカラム（直径10cm,
長さ120cm）に通し、メタノールで800ml/hの流量速度で
溶出する。After that, add 1/25 volume of methanol of the extracted culture solution, dissolve and dissolve it in a separator with a lid made of polycarbonate with a diameter of 60 mm, 100 mm and an internal volume of 250 ml and set it in a centrifuge (centrifuge (10,000 rpm). For 10 minutes), and the supernatant was swelled with methanol for 3 minutes, and the column was packed with a stationary phase (diameter 10 cm,
120 cm) and elute with methanol at a flow rate of 800 ml / h.
検出には254nmの波長に対する吸光度を計測する紫外線
検出器を使用し、図に示すように、7.25〜9.0時間に流
出する区分より分画を得た。なお、チャートスピードは
4cm/hourである。For detection, an ultraviolet detector that measures absorbance at a wavelength of 254 nm was used, and as shown in the figure, fractions were obtained from the section flowing out at 7.25 to 9.0 hours. The chart speed is
It is 4 cm / hour.
次に、このようにして採取した分画を10mmHg、40℃で減
圧蒸発乾固し、さらにこれを100倍濃度の濃縮水溶液と
する。Next, the fraction thus collected is evaporated to dryness under reduced pressure at 10 mmHg and 40 ° C., and this is made into a concentrated aqueous solution having a concentration of 100 times.
４）検定 （イ）24穴培養皿に２×105個／穴のヒト腎細胞癌由来
樹立株細胞HRCを植え込み、実験群を10％牛胎児血清を
Ｅ−MEMに混合したものを培地として各穴に1.5ml加え、
37℃,5％CO2,100％湿度で培養する。１日おきに培地交
換し、７日目に細胞数を計り増殖を調べた。4) Assay (a) 2 × 10 5 cells / well of human renal cell carcinoma-derived established cell line HRC were implanted in a 24-well culture dish, and the experimental group was prepared by mixing 10% fetal bovine serum with E-MEM as a medium. Add 1.5 ml to each hole,
Incubate at 37 ℃, 5% CO 2 and 100% humidity. The medium was replaced every other day, and the number of cells was measured on the 7th day to examine the growth.
対照標準として新鮮培地で培養したヒト腎細胞癌由来樹
立株細胞HRCの数を100％とし、分画を原液に換算して10
倍濃度としたものをＡとし、５倍濃度としたものをＢと
して新鮮培地に投与してその影響を検べた結果を第１表
に示す。As a reference standard, the number of established HRC cells derived from human renal cell carcinoma cultured in fresh medium was set to 100%, and the fractions were
Table 1 shows the results of examining the effect of a double concentration of A and a 5-fold concentration of B on fresh medium.
（ロ）マウスにC57BLを用い、このマウスにマウスルイ
ス肺癌細胞106個を側背部皮下に移植し、分画の50倍濃
縮水溶液を１日２回0.25ml注射によって投与し、投与８
日目の腫瘍の縦×横の大きさ及び投与12日目の解剖によ
る腫瘍の重量を計測した。対照標準に対する計測値を第
２表及び第４表に示す。 (B) C57BL was used as a mouse, and 10 6 mouse Lewis lung cancer cells were subcutaneously transplanted into the dorsal region of the back of the mouse, and a 50-fold concentrated aqueous solution of the fraction was administered twice a day by 0.25 ml injection to give 8 doses.
The length × width size of the tumor on the day and the weight of the tumor on the 12th day after administration were measured. The measured values for the control are shown in Tables 2 and 4.
図は、本発明の動物の悪性腫瘍細胞増殖抑制剤の分画抽
出を示す線図である。The figure is a diagram showing the fractional extraction of the malignant tumor cell growth inhibitor of the animal of the present invention.
Claims (1)
た後、抽出用培地に移して35〜37℃で培養し、前記悪性
腫瘍細胞を除いたものを、メタノールで膨潤したビーズ
状のハイドロキシプロピル化デキストランゲルよりなる
固定相を直径10cm,長さ120cm充填したカラムで１時間80
0ミリリットルの流量で溶出し、7.25〜9.0時間の間に流
出する区分を分取したものよりなることを特徴とする人
を含む動物の悪性腫瘍細胞増殖抑制剤。1. A malignant tumor cell of an animal including a human being cultured and proliferated, transferred to an extraction medium and cultured at 35 to 37 ° C., and excluding the malignant tumor cell, a bead-shaped product swollen with methanol A stationary phase composed of hydroxypropylated dextran gel was packed in a column packed with a diameter of 10 cm and a length of 120 cm for 80 hours for 1 hour.
An agent for suppressing the growth of malignant tumor cells in animals, including humans, which is characterized in that it is eluted at a flow rate of 0 ml and is collected in a fraction flowing out during 7.25 to 9.0 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61148129A JPH0729932B2 (en) | 1986-06-26 | 1986-06-26 | Animal malignant tumor cell growth inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61148129A JPH0729932B2 (en) | 1986-06-26 | 1986-06-26 | Animal malignant tumor cell growth inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS635025A JPS635025A (en) | 1988-01-11 |
| JPH0729932B2 true JPH0729932B2 (en) | 1995-04-05 |
Family
ID=15445905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61148129A Expired - Fee Related JPH0729932B2 (en) | 1986-06-26 | 1986-06-26 | Animal malignant tumor cell growth inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0729932B2 (en) |
-
1986
- 1986-06-26 JP JP61148129A patent/JPH0729932B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS635025A (en) | 1988-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11135160B2 (en) | Use of chlorogenic acid in preparing pharmaceuticals for treatment of LAG-3-mediated disease | |
| US4755504A (en) | Pharmaceutical composition from Tienchi | |
| CN107213145A (en) | Application of the Rabdocetsin B in the product for suppressing esophageal squamous cell cancer cell multiplication is prepared | |
| JPH0729932B2 (en) | Animal malignant tumor cell growth inhibitor | |
| JPH0729931B2 (en) | Animal malignant tumor cell growth inhibitor | |
| JPH0720871B2 (en) | Animal malignant tumor cell growth inhibitor | |
| CN109097363A (en) | A kind of biological recombination type miR34a-5p that Growth of Osteosarcoma can be effectively suppressed | |
| JPH0729933B2 (en) | Animal malignant tumor cell growth inhibitor | |
| JPH0729934B2 (en) | Animal malignant tumor cell growth inhibitor | |
| CN110776409B (en) | Method for extracting pterocarpus indicus and application of extract in antitumor drugs | |
| Laurence et al. | Epidermal chalone and cell proliferation in a transplantable squamous cell carcinoma in hamsters: II. In vitro Results | |
| Colter et al. | Immunological studies with protein fractions isolated from Ehrlich ascites carcinoma cells | |
| US5711948A (en) | Plant-derived, biologically active polysaccharides and method of preparing same | |
| Schwartz et al. | Actinomycin D effects on nucleic acids during tumor regression | |
| CN115778965B (en) | New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine | |
| CN109022442A (en) | A kind of biological recombination type miR124-3p that Growth of Osteosarcoma can be effectively suppressed | |
| CN114209728B (en) | Wild chrysanthemum active site with function of regulating epigenetic expression balance and resisting liver cancer as well as preparation method and application thereof | |
| JPS60178820A (en) | Preparation of antitumor active substance | |
| CN105920046B (en) | A kind of polar glycolipids extract and its application | |
| CA1330346C (en) | Caffeic acid esters and methods of preparing and using same | |
| SU967484A1 (en) | Method of producing alpha-fucosospecific lectine | |
| JP3490757B2 (en) | Neutrophil activator | |
| JP2002521341A (en) | Cow dung extract having anti-cancer and anti-inflammatory effects and method for producing the same | |
| JPH10509028A (en) | Cell growth regulator | |
| KR20000016714A (en) | Vegetable extract, method for preparation thereof and its applications in human and veterinary medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |